Zhi Tong Cai Jing·2026-01-06 01:42Core Viewpoint - CICC has raised JD Health's revenue forecasts for 2025 and 2026 by 2% to 72.5 billion yuan and 81.7 billion yuan respectively, driven by the ongoing growth of original drug categories and strong demand for flu products [1] Group 1: Revenue Performance - The company is expected to show strong revenue growth, with a projected year-on-year increase of nearly 25% for the entire year of 2025, supported by the continuous release of original drugs and the rising demand for flu prevention since Q4 2025 [2] - In the first three quarters of 2025, the company achieved a quarterly revenue growth rate of approximately 25% year-on-year [2] Group 2: Profitability Outlook - The company's non-IFRS net profit margins for the first three quarters of 2025 were 10.6%, 9.7%, and 11.1%, showing varying degrees of improvement year-on-year, primarily due to increased advertising and marketing investments by pharmaceutical and health product companies [3] - Despite the typical increase in expenditures during Q4 2025, the company is expected to maintain a stable profit margin for the year, reflecting strong competitive capabilities [3] - The company has significant cash reserves, and potential fluctuations in interest income due to interest rate cuts may impact non-IFRS net profit in the coming quarters [3]